Featured Post from ChristianaCare

New Access to Health Care Comes to Kingswood Community Center: ChristianaCare Virtual Health at The Coker Family Resource Center

Jun 11, 2021

6 min

A new model of health care is coming to Wilmington’s Riverside neighborhood and the Kingswood Community Center. ChristianaCare Virtual Health is now available at The Coker Family Resource Center, inside Kingswood Community Center. It offers convenient, personalized, always-accessible care that makes it easier for people to connect with the care they need and stay well.


“This is an entirely new model of health care powered by data and technology to make it easier for people to access care when they need it, and one that fosters strong relationships between patients and their care team,” said Janice E. Nevin, M.D., MPH, president and CEO of ChristianaCare. “In our commitment to make a positive impact on health for everyone in the communities we serve, we’re excited to bring this leading-edge model of care to our neighbors at Riverside. We’re grateful for the partnership of The WRK Group and Kingswood Community Center in this collaborative effort that will support the health and wellbeing of the people in this community.”




At The Coker Family Resource Center, patients can connect to ChristianaCare Virtual Health for a virtual appointment with a primary care provider or a member of their care team and also receive access to medical services such as vaccines, blood pressure checks and in-person exams. But care doesn’t have to happen at Kingswood Community Center. Patients can have a virtual visit with their care team anytime and from anywhere they have access to the internet with a smartphone, tablet or laptop with a camera.


“Throughout the pandemic, many people have learned the convenience of having a video visit with their doctor instead of coming in for an in-person appointment. At ChristianaCare, we’ve actually been developing this kind of care since the launch of our Virtual Primary Care practice for ChristianaCare caregivers in 2018, in addition to our CareVio data-powered care management platform,” said Sharon Anderson, RN, MS, FACHE, chief virtual health officer at ChristianaCare. “What we’re able to provide today is not just video visits, but an entirely new kind of care that’s always on—it enables patients to interact with their care team when they need support through video visits, secure text messages and other ways that provide care in ways that fit into each person’s lifestyle.”



Sharon Anderson, RN, MS, FACHE, chief virtual health officer at ChristianaCare


In addition to the on-site medical services provided at the Kingswood location, patients can also receive in-person help with the technology so that they can become comfortable with this new model of care, and ask questions or get help when they need it.


Kingswood Community Center, a member of The WRK Group (The Warehouse, REACH Riverside, and Kingswood Community Center), has been a pillar of the Riverside community for 75 years and is located at 2300 Bowers St, Wilmington, DE 19802. In-person appointments are available every Tuesday and Thursday from 12:30 – 2:30 (times may vary). Information and appointments are available by calling 302-428-2400.


Establishing easily accessible health care within the Riverside neighborhood marks a long-time goal of The WRK Group.


“We are incredibly thankful for this partnership with ChristianaCare Virtual Health as they become the first primary care service provider that exists within Riverside,” said Logan S. Herring, Sr., CEO of The WRK Group. “ChristianaCare has created a nimble solution for our neighbors that includes valuable in-person services and care as well as virtual appointments. Creating this physical and virtual space is an achievement for our community and one in a series of initiatives The WRK Group plans to bring to the local area.”


The WRK’s Group managing partner, REACH Riverside, is currently overseeing a $250M holistic revitalization project which includes building a new and improved community center, developing a mixed income housing community, and investing in physical capital to create a thriving and vibrant neighborhood.


Introducing the Coker Family Resource Center


The Coker Family Resource Center is a new addition to the Kingswood Community Center, made possible by the generous donation of the Coker family, a pillar in the Riverside and Wilmington community. From matriarch and civil rights leader Beatrice “Bebe” Coker and her activism efforts to daughters Dr. Joan Coker, Laurie Coker Reid, and Julie Coker's collective philanthropic and community work, the Coker family embodies the values of Kingswood Community Center and The WRK Group’s collective mission to empower the community to reach its full potential.


“Thank you to the entire Coker family, who have dedicated themselves to bettering our community for decades, as well as for providing the needed funding to create the physical space that ChristianaCare Virtual Health inhabits,” Herring continued. “The Coker family has once again demonstrated the value of believing and investing in their community. As we look to the future and continue to dream big about the new Kingswood Community Center, I am excited by the prospect of what this space will evolve into and what additional services we can offer our community.”


For more information about ChristianaCare Virtual Care at Kingswood Community Center, click here.


About ChristianaCare


Headquartered in Wilmington, Delaware, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,299 beds), a freestanding emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women’s health. It also includes the pioneering Gene Editing Institute.


ChristianaCare is nationally recognized as a great place to work, rated by Forbes as the 5th best health system to work for in the United States and by IDG Computerworld as one of the nation’s Best Places to Work in IT. ChristianaCare is rated by HealthGrades as one of America’s 50 Best Hospitals and continually ranked among the nation’s best by U.S. News & World Report, Newsweek and other national quality ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.


About The WRK Group


The WRK Group, which is comprised of three organizations and over 130 employees, shares a collective mission to empower the community to reach its full potential by eliminating the barriers of structural racism and revolutionizing teen engagement. REACH Riverside, overseeing a $250M holistic revitalization, also serves as the managing partner for Kingswood Community Center, a pillar of the Northeast Wilmington neighborhood for 75 years, and The Warehouse, an educational and recreational oasis for teens.


The Warehouse:


Developed "For Teens, By Teens" - Innovative, one-stop center serving ages 13 to 19

Teen-driven programming focused on recreation, education, arts, career, and health

Collaborating with over 140 youth-serving organizations

Three goals: safety, educational support, and workforce readiness

REACH Riverside:


Developed "With the Community, For the Community"

Member of the national Purpose Built Communities

Redevelopment: Up to 600 units of high quality, mixed-income housing

Education: cradle-to-college and career readiness pipeline

Community Health: health, wellness, safety services, and programming

Kingswood Community Center


Empowering the Community of Riverside and Northeast Wilmington since 1946

Early Learning Academy: high quality, evidence-based programming (ages one through five)

School-age services (ages six through twelve): before, after-school, and summer programming

Jimmy Jenkins Senior Center: activities to remain healthy and self-sufficient

Kingswood Academy: alternative school, located at The Warehouse (seventh through twelfth grade)

Preparing for the development of a new, state-of-the-art facility that will replace and enhance the current community center

####

You might also like...

Check out some other posts from ChristianaCare

3 min

Expanding Comprehensive Cancer Services to Middletown, Delaware

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is expanding access to high-quality, comprehensive cancer care for residents in Middletown and nearby communities. These services will be offered at the new Middletown Health Center, now under construction and expected to open in May 2027. “Our vision is to expand and grow our services throughout the region so that more patients can access high-quality cancer care close to home,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute. “By bringing our full cancer-care team and advanced technology to Middletown, we can provide highly precise, coordinated treatment while maintaining the same high standard of care our patients expect.” The cancer care services offered at the Middletown Health Center will reflect the same high-quality, comprehensive care provided at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute in Newark. Patients will have access to specialists across all major cancer types, supported by the Graham Cancer Center’s participation in the National Cancer Institute Community Oncology Research Program (NCORP), which brings advanced treatments and clinical trials directly to the community. In Middletown, this means coordinated multidisciplinary treatment planning, advanced radiation therapy, infusion services, consultations with oncologists and surgeons, nurse navigation, supportive care, clinical trial participation and both in-person and virtual visit options. Advanced Technology Enhances Precision and Comfort When services open in Middletown, patients will have access to advanced radiation therapy using the Varian TrueBeam linear accelerator, one of the most sophisticated radiation therapy systems available. TrueBeam delivers highly precise, image-guided treatments for a wide range of cancers, allowing physicians to target tumors more accurately while minimizing radiation to healthy tissue. “The TrueBeam system represents a major step forward in how we deliver radiation therapy,” said Adam Raben, M.D., chair of Radiation Oncology at ChristianaCare. “Treatments that once took 30 minutes can now be completed in just a few minutes, with real-time imaging ensuring precision. This means better tumor control, fewer side effects and a more comfortable experience for patients.” A Growing Community with Expanding Health Care Needs Middletown is one of Delaware’s fastest-growing communities, with its population projected to rise 8% by 2029, nearly twice the statewide rate, according to the US Census Bureau. Since 1990, the town’s population has grown more than 550%, and the number of residents age 65 and older has increased 24% since 2020, driving demand for accessible, high-quality health care. With continued growth and an aging population, cancer service demand in Middletown is expected to increase by 11% over the next decade, according to health care forecasts from Sg2, a Vizient company, underscoring the need for expanded local care options. Expanding Access to Meet Future Cancer Care Demand By expanding services in Middletown, ChristianaCare is responding to both the region’s population growth and the increasing need for cancer care. The new site will help patients receive timely diagnosis and treatment while reducing travel time and improving coordination with the full Graham Cancer Center team. “As our community grows, so too does the need for locally accessible, state-of-the-art cancer services,” said Schwaab. “This expansion represents a pivotal investment in the health of the Middletown—Odessa—Townsend corridor and beyond.” $92 Million Investment in Middletown’s Health The $92.3 million Middletown Health Center reflects a deep investment in the health and vitality of the state. It is part of ChristianaCare’s larger plan, announced in July 2025, to invest more than $865 million in Delaware over the next three years. In addition to cancer care, the Middletown Health Center will offer a full range of services, including primary and specialty care, women’s health, behavioral health, cardiovascular care, pediatrics, neurology, imaging, diagnostics and lab testing. The center’s healing environment will also include walking trails and abundant natural light, making high-quality, convenient and coordinated care more accessible and welcoming for patients and families. The 87,000-square-foot Health Center will be located at 621 Middletown Odessa Road, next to ChristianaCare’s existing freestanding emergency department.

3 min

ChristianaCare Launches Organoid Core to Personalize Cancer Treatment

ChristianaCare’s Cawley Center for Translational Cancer Research has unveiled a first-of-its-kind organoid core in a community cancer center program. The new laboratory facility within the Helen F. Graham Cancer Center & Research Institute grows and tests living, patient-derived tumor models, giving doctors and researchers a faster, more precise way to identify the therapies most likely to work for each patient. This innovation could change how cancer is treated in Delaware and serve as a model for community centers nationwide. There are only a handful of organoid core centers, or “tumor-on-a-chip” programs, in the United States, and ChristianaCare’s is the first within a community cancer center setting. What the Organoid Core Does Tumor organoids are tiny, three-dimensional cultures grown from a patient’s tumor tissue. They preserve the genetic and molecular traits of the original tumor, making them far more accurate than traditional cell lines. “These mini-tumors enable researchers to screen drugs faster, identify new biomarkers and discover which treatments are most likely to work for each patient,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “This core is a bridge between the lab and the clinic. By growing living tumor models from cells of individual patients, we can test real-world drug responses and tailor treatments for them in ways that were not possible before.” How It Advances Patient Care The organoid core strengthens the Cawley Center's research capabilities by enabling drug screening and biomarker discovery. It will bank organoids representing the wide variety of tumors seen in the community, giving scientists a realistic system for testing therapies. ChristianaCare treats more than 70 percent of cancer patients in Delaware, giving researchers unique access to treatment-naïve samples. These are tumor tissues that have not yet been exposed to chemotherapy or other therapies. Studying them provides a more accurate picture of how cancer behaves naturally and how it might respond to new treatments. Bringing a new cancer drug to patients is expensive and risky. Estimates show it can cost $1.3 to $2.8 billion, with up to a third spent on preclinical development, and only about one in 10 compounds ever reach human trials. Traditional mouse models often fail to fully mimic human tumors, making early testing less reliable. By using organoid screening, the Cawley Center can test therapies more accurately, reduce costs and failure rates and move promising treatments into clinical trials faster. Combined with existing tissue collection programs, clinical trial infrastructure and community partnerships, these resources create a direct pathway to bring lab discoveries to patients faster. Turning Point in Translational Research “Our goal is to shorten the distance between discovery and treatment,” said Nicholas J. Petrelli, M.D., director of the Cawley Center. “Too many promising drugs fail because early models do not capture the complexity of real tumors. The organoid core helps solve that problem. We can now test therapies in models that reflect the patients we actually serve.” “This is a turning point for translational research in community health,” said Jennifer Sims Mourtada, Ph.D., associate director at the Cawley Center. “Organoid technology lets us study cancer in a way that feels personal. We are not just looking at data points. We are studying living models of a patient’s tumor, which can reveal how that person’s cancer might behave or respond to treatment. This approach brings science closer to the people it is meant to help.” Looking Ahead In the coming months, the organoid core will focus on building a diverse biobank of tumors common in Delaware. Plans include collaborations with academic institutions, shared access for external researchers, and development of immune-tumor co-culture models. By combining advanced technology, strong community partnerships and direct patient access, ChristianaCare and the Cawley Center are showing how translational cancer research can thrive in a community setting, making breakthroughs not only in the lab but also in patients’ lives.

3 min

ChristianaCare Gene Editing Institute Achieves CRISPR Breakthrough That Reverses Chemotherapy Resistance in Lung Cancer

In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings were published Nov. 13, 2025 in the online edition of Molecular Therapy Oncology. This breakthrough stems from more than a decade of research by the Gene Editing Institute into the NRF2 gene, a known driver of treatment resistance. The results were consistent across multiple in vitro studies using human lung cancer cell lines and in vivo animal models. “We’ve seen compelling evidence at every stage of research,” said Kelly Banas, Ph.D., lead author of the study and associate director of research at the Gene Editing Institute. “It’s a strong foundation for taking the next step toward clinical trials.” Potential Beyond Lung Cancer The study focused on lung squamous cell carcinoma, an aggressive and common form of non-small cell lung cancer (NSCLC) that accounts for 20% to 30% of all lung cancer cases, according to the American Cancer Society. It’s estimated that over 190,000 people in the U.S. will be diagnosed in 2025. While the research centered on this cancer type, the implications are broader. Overactive NRF2 contributes to chemotherapy resistance in several solid tumors, including liver, esophageal and head and neck cancers. The results suggest a CRISPR-based strategy targeting NRF2 could help resensitize a wide range of treatment-resistant tumors to standard chemotherapy. “This is a significant step toward overcoming one of the biggest challenges in cancer therapy — drug resistance,” Banas said. “By targeting a key transcription factor that drives resistance, we’ve shown that gene editing can re-sensitize tumors to standard treatment. We’re hopeful that in clinical trials and beyond, this is what will allow chemotherapy to improve outcomes for patients and could enable them to remain healthier during the entirety of their treatment regimen.” Targeting a Master Switch for Resistance The research zeroed in on a tumor-specific mutation, R34G, in the NRF2 gene, which acts as a master regulator of cellular stress responses. When overactive, NRF2 helps cancer cells withstand chemotherapy. Using CRISPR/Cas9, the team engineered lung cancer cells with the R34G mutation and successfully knocked out NRF2. This restored sensitivity to chemotherapy drugs such as carboplatin and paclitaxel. In animal models, tumors directly treated with CRISPR to knockout NRF2 grew more slowly and responded better to treatment. “This work brings transformational change to how we think about treating resistant cancers,” said Eric Kmiec, Ph.D., senior author of the study and executive director of the Gene Editing Institute. “Instead of developing entirely new drugs, we are using gene editing to make existing ones effective again.” Editing Reaches Threshold Levels One of the most promising discoveries was that disrupting NRF2 in just 20% to 40% of tumor cells, was enough to improve the response to chemotherapy and shrink tumors. This insight is particularly relevant for clinical use, where editing every cancer cell may not be feasible. To test therapy in mice, the researchers used lipid nanoparticles (LNPs), a non-viral method with high efficiency and low risk of unintended, off-target effects. Sequencing confirmed that the edits were highly specific to the mutated NRF2 gene, with minimal unintended changes elsewhere in the genome. “The power of this CRISPR therapy lies in its precision. It’s like an arrow that hits only the bullseye,” said Banas. “This level of specificity with minimal unanticipated genomic side effects offers real hope for the cancer patients who could one day receive this treatment.”

View all posts
Powered by